About Neurexis Therapeutics
Neurexis Therapeutics is a company based in Aurora (United States) founded in 2020.. Neurexis Therapeutics has raised $605 thousand across 7 funding rounds from investors including NIH, HHS and Colorado Office of Economic Development and International Trade. Neurexis Therapeutics offers products and services including tatCN19o. Neurexis Therapeutics operates in a competitive market with competitors including Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Proniras, among others.
- Headquarter Aurora, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neurexis Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$605 K (USD)
in 7 rounds
-
Latest Funding Round
$3 M (USD), Grant
Sep 18, 2024
-
Investors
NIH
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neurexis Therapeutics
Neurexis Therapeutics offers a comprehensive portfolio of products and services, including tatCN19o. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Peptide that reduces brain damage after ischemic events like stroke.
Unlock access to complete
Unlock access to complete
Funding Insights of Neurexis Therapeutics
Neurexis Therapeutics has successfully raised a total of $605K across 7 strategic funding rounds. The most recent funding activity was a Grant round of $3 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Grant — $3.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Grant - Neurexis Therapeutics | Valuation |
investors |
|
| May, 2022 | Amount | Seed - Neurexis Therapeutics | Valuation |
investors |
|
| Sep, 2021 | Amount | Grant - Neurexis Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neurexis Therapeutics
Neurexis Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Colorado Office of Economic Development and International Trade. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
High-impact life science companies are developed by VIC Tech.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neurexis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Neurexis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neurexis Therapeutics Comparisons
Competitors of Neurexis Therapeutics
Neurexis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Proniras, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic solution for the repair of cut and crushed peripheral nerves.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for retina and brain diseases
|
|
| domain | founded_year | HQ Location |
Developer of cytoprotective therapy for traumatic brain injury
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for seizures and brain injury treatment.
|
|
| domain | founded_year | HQ Location |
Novel therapies for acute neurological conditions are developed and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neurexis Therapeutics
Frequently Asked Questions about Neurexis Therapeutics
When was Neurexis Therapeutics founded?
Neurexis Therapeutics was founded in 2020.
Where is Neurexis Therapeutics located?
Neurexis Therapeutics is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
Is Neurexis Therapeutics a funded company?
Neurexis Therapeutics is a funded company, having raised a total of $605K across 7 funding rounds to date. The company's 1st funding round was a Grant of $1.43M, raised on Apr 08, 2020.
What does Neurexis Therapeutics do?
Neurexis Therapeutics was founded in 2020 and is based in Aurora, United States, within the biotechnology sector. Focus is placed on developing therapeutic peptides, such as the 30-amino acid tatCN19o, which features a domain for blood-brain barrier penetration and another for inhibiting Ca2calmodulin-dependent protein kinase II (CaMKII). Operations center on advancing these peptides for neuroprotective applications in neurological conditions.
Who are the top competitors of Neurexis Therapeutics?
Neurexis Therapeutics's top competitors include Tonix Pharma, Neuraptive and Edge Therapeutics.
What products or services does Neurexis Therapeutics offer?
Neurexis Therapeutics offers tatCN19o.
Who are Neurexis Therapeutics's investors?
Neurexis Therapeutics has 4 investors. Key investors include NIH, HHS, Colorado Office of Economic Development and International Trade, and VIC Tech.